Mutual Fund Summary Prospectus (497k)
July 30 2013 - 1:40PM
Edgar (US Regulatory)
Before you invest, you may wish to review
the Funds Prospectus, which contains more information about the Fund and its risks. You may obtain the Prospectus and other information about the Fund, including the Statement of Additional Information (SAI) and most recent reports to
shareholders, at no cost by visiting http://guggenheiminvestments.com/services/prospectuses-and-reports, calling 800.820.0888 or
e-mailing
services@guggenheiminvestements.com. The Funds Prospectus and
SAI, both dated August 1, 2013, as revised from time to time, and the Funds most recent shareholder reports, are incorporated by reference into this Summary Prospectus.
SUMBTIA-0813x0814
Biotechnology Fund
INVESTMENT OBJECTIVE
The Biotechnology Fund (the Fund) seeks to provide capital appreciation by investing in companies that are involved in the biotechnology
industry, including companies involved in research and development, genetic or other biological engineering, and in the design, manufacture, or sale of related biotechnology products or services (Biotechnology Companies).
FEES AND EXPENSES OF THE FUND
This table
describes the fees and expenses that you may pay if you buy and hold Advisor Class Shares or Investor Class Shares of the Fund.
|
|
|
|
|
|
|
|
|
|
|
Advisor
Class Shares
|
|
|
Investor
Class Shares
|
|
SHAREHOLDER FEES
(fees paid directly from
your investment)
|
|
|
N/A
|
|
|
|
N/A
|
|
ANNUAL FUND OPERATING EXPENSES
(expenses that you pay each year as a percentage of the value of your
investment)
|
|
|
|
|
|
|
|
|
Management Fees
|
|
|
0.85%
|
|
|
|
0.85%
|
|
Distribution and Shareholder Service (12b-1) Fees
|
|
|
0.25%
|
|
|
|
None
|
|
Other Expenses
|
|
|
0.76%
|
|
|
|
0.50%
|
|
Total Annual Fund Operating Expenses
|
|
|
1.86%
|
|
|
|
1.35%
|
|
EXAMPLE
This Example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds.
The Example assumes that you invest $10,000 in the Fund for the time periods indicated, and then redeem all of your shares at the end of those
periods. The Example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Year
|
|
|
3 Years
|
|
|
5 Years
|
|
|
10 Years
|
|
Advisor Class Shares
|
|
$
|
189
|
|
|
$
|
585
|
|
|
$
|
1,006
|
|
|
$
|
2,180
|
|
Investor Class Shares
|
|
$
|
137
|
|
|
$
|
428
|
|
|
$
|
739
|
|
|
$
|
1,624
|
|
PORTFOLIO TURNOVER
The Fund pays transaction costs, such as commissions, when it buys and sells securities (or turns over its portfolio). A higher portfolio turnover rate may indicate higher transaction
costs and may result in higher taxes when Fund shares are held in a taxable account. These costs, which are not reflected in Total Annual Fund Operating Expenses or in the Example, affect the Funds performance. During the most recent fiscal
year, the Funds portfolio turnover rate was 197% of the average value of its portfolio. The Funds portfolio turnover rate is calculated without regard to cash instruments or derivatives. If such instruments were included, the Funds
portfolio turnover rate might be significantly higher.
PRINCIPAL INVESTMENT STRATEGIES
Under normal circumstances, the Fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in
derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. The Fund will invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized
capitalizations. Biotechnology Companies are engaged in the research, development, and manufacture of various biotechnological products, services, and processes; manufacture and/or distribute biotechnological and biomedical products, including
devices and instruments; provide or benefit significantly from scientific and technological advances in biotechnology; or provide processes or services instead of, or in addition to, products. The Fund also may purchase American Depositary Receipts
(ADRs) to gain exposure to foreign Biotechnology Companies and U.S. government securities. In an effort to ensure that the Fund is fully invested on a day-to-day basis, the Fund may conduct any necessary trading activity at or just prior
to the close of the U.S. financial markets. The Fund invests in the securities of a limited number of issuers conducting business in the biotechnology sector and, therefore, may be concentrated in an industry or group of industries within the
biotechnology sector. The Fund is non-diversified and, therefore, may invest a greater percentage of its assets in a particular issuer in comparison to a diversified fund.
PRINCIPAL RISKS
As with all mutual funds, a shareholder is subject to the risk that his or her investment could lose money. In addition to this risk, the Fund is subject to a number of additional risks that may
affect the value of its shares, including:
Active Trading Risk
Active trading, also called high portfolio
turnover, may result in higher brokerage costs or mark-up charges, which may negatively affect Fund performance. High portfolio turnover may also result in high levels of short-term capital gains, which are generally taxable as ordinary income
when distributed to shareholders. Large movements of assets into and out of the Fund due to active trading also may adversely affect the Funds ability to achieve its investment objective.
Biotechnology Sector Risk
To the extent that the Funds investments are exposed to issuers conducting business in the biotechnology
sector, the Fund is subject to the risk that the securities of such issuers will underperform the market as a whole due to legislative or regulatory changes, adverse market conditions and/or increased competition affecting that economic sector. The
prices of the securities of Biotechnology Companies also may fluctuate widely in response to such events.
Depositary Receipt
Risk
The Fund may hold the securities of non-U.S. companies in the form of ADRs. The underlying securities of the ADRs in the Funds portfolio are subject to fluctuations in foreign currency exchange rates that may affect the value of
the Funds portfolio. In addition, the value of the securities underlying the ADRs may change materially when the U.S. markets are not open for trading. Investments in the underlying foreign securities also involve political and economic risks
distinct from those associated with investing in the securities of U.S. issuers.
Derivatives Risk
The Funds
investments in derivatives may pose risks in addition to those associated with investing directly in securities or other investments, including illiquidity of the derivatives, imperfect correlations with underlying investments or the Funds
other portfolio holdings, lack of availability and counterparty risk. The Fund could lose more than the principal amount invested.
Early Closing Risk
The Fund is subject to the risk that unanticipated early closings of securities exchanges and other financial markets
may result in the Funds inability to buy or sell securities or other financial instruments on that day and may cause the Fund to incur substantial trading losses.
Equity Risk
The Fund is subject to the risk that the value of the equity securities or equity-based derivatives in the Funds portfolio will decline due to volatility in the equity
market caused by general market and economic conditions, perceptions regarding particular industries represented in the equity market, or factors relating to specific companies to which the Fund has investment exposure.
Foreign Issuer Exposure Risk
The Fund may invest in securities of foreign companies directly, or in financial instruments, such as ADRs,
that are indirectly linked to the performance of foreign issuers. Foreign securities markets generally have less trading volume and less liquidity than U.S. markets, and prices in some foreign markets may fluctuate more than those of securities
traded on U.S. markets.
Market Risk
The Funds investments in securities and derivatives, in general, are subject to
market risks that may cause their prices, and therefore the Funds value, to fluctuate over time. An investment in the Fund may lose money.
Mid-Capitalization Securities Risk
The Fund is subject to the risk that medium-capitalization stocks may underperform other segments of the equity market or the equity market as a whole.
Non-Diversification Risk
The Fund is considered non-diversified and can invest a greater portion of its assets in securities
of individual issuers than a diversified fund. As a result, changes in the market value of a single security could cause greater fluctuations in the value of Fund shares than would occur in a diversified fund.
Small-Capitalization Securities Risk
The Fund is subject to the risk that small-capitalization stocks may underperform other segments of
the equity market or the equity market as a whole.
Temporary Defensive Investment Risk
The Fund does not attempt to take
defensive positions in declining markets. Therefore, the Fund may be subject to greater losses in a declining market than a fund that does take defensive positions in declining markets.
Trading Halt Risk
If a trading halt occurs, the Fund may temporarily be unable to purchase or sell securities, options or futures contracts. Such a trading halt near the time the Fund
prices its shares may limit the Funds ability to use leverage and may prevent the Fund from achieving its investment objective.
PERFORMANCE INFORMATION
The following bar chart shows the performance of the Investor Class Shares of the Fund from year to year. The variability of performance over time provides an indication of the risks of investing in
the Fund. The following tables show the performance of the Advisor Class Shares and Investor Class Shares of the Fund as an average over different periods of time in comparison to the performance of a broad-based market index. The figures in the bar
chart and tables assume the reinvestment of dividends and capital gains distributions. Of course, this past performance (before and after taxes) does not necessarily indicate how the Fund will perform in the future.
Updated performance information is available on the Funds website at www.guggenheiminvestments.com or by calling Guggenheim Investments Client
Services at 800.820.0888.
The performance information shown below for Investor Class Shares is based on a calendar year. The
year-to-date return for the period from January 1, 2013 through June 30, 2013 is 24.71%.
|
|
|
Highest Quarter Return
|
|
Lowest Quarter Return
|
(quarter ended 6/30/2003) 26.91%
|
|
(quarter ended 6/30/2010) -16.79%
|
AVERAGE ANNUAL TOTAL RETURN
(for periods ended December 31, 2012)
The after-tax returns presented in the table below are calculated using highest historical individual federal marginal income tax rates and do not
reflect the impact of state and local taxes. Your actual after-tax returns will depend on your specific tax situation and may differ from those shown below. After-tax returns are not relevant to investors who hold shares of the Fund through
tax-deferred arrangements, such as 401(k) plans or individual retirement accounts.
|
|
|
|
|
|
|
|
|
|
|
|
|
Advisor Class Shares
|
|
Past
1 Year
|
|
|
Past
5 Years
|
|
|
Past
10 Years
|
|
Return Before Taxes
|
|
|
35.85%
|
|
|
|
11.87%
|
|
|
|
11.31%
|
|
Return After Taxes on Distributions
|
|
|
35.85%
|
|
|
|
11.87%
|
|
|
|
11.31%
|
|
Return After Taxes on Distributions and Sale of Fund Shares
|
|
|
23.30%
|
|
|
|
10.40%
|
|
|
|
10.16%
|
|
S&P 500
®
Index
(reflects no deduction for fees, expenses or taxes)
|
|
|
16.00%
|
|
|
|
1.66%
|
|
|
|
7.10%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investor Class Shares
|
|
Past
1 Year
|
|
|
Past
5 Years
|
|
|
Past
10 Years
|
|
Return Before Taxes
|
|
|
36.54%
|
|
|
|
12.45%
|
|
|
|
11.87%
|
|
Return After Taxes on Distributions
|
|
|
36.54%
|
|
|
|
12.45%
|
|
|
|
11.87%
|
|
Return After Taxes on Distributions and Sale of Fund Shares
|
|
|
23.75%
|
|
|
|
10.91%
|
|
|
|
10.68%
|
|
S&P 500
®
Index
(reflects no deduction for fees, expenses or taxes)
|
|
|
16.00%
|
|
|
|
1.66%
|
|
|
|
7.10%
|
|
MANAGEMENT
INVESTMENT
ADVISOR
Security Investors, LLC, which operates under the name Guggenheim Investments, serves as the investment adviser of the Fund.
PORTFOLIO MANAGERS
|
|
|
Michael P. Byrum,
CFA, Senior Vice President. Mr. Byrum has been associated with the Advisor since 1993.
|
|
|
|
Michael J. Dellapa,
CFA, CAIA, Portfolio Manager. Mr. Dellapa has been associated with the Advisor since 2000.
|
|
|
|
Ryan A. Harder,
CFA, Portfolio Manager. Mr. Harder has been associated with the Advisor since 2004.
|
PURCHASE AND SALE OF FUND SHARES
Advisor
Class Shares and Investor Class Shares held through a third party (
e.g.,
a brokerage account) are subject to the following minimum initial investment amounts:
|
|
|
$1,000 for retirement accounts
|
|
|
|
$2,500 for all other accounts
|
Advisor Class Shares held directly at Guggenheim Investments generally do not require a minimum investment amount. For Investor Class Shares, non-managed accounts (including retirement accounts)
held directly at Guggenheim Investments generally require a minimum account balance of $5,000. Accounts managed by financial professionals are not subject to minimum account balance requirements. However, accounts opened through a financial
intermediary (non-direct) will be subject to your financial intermediarys minimum initial investment amount and account balance requirements, which may be different than the amounts above.
There are no minimum amounts for subsequent investments in the Fund except for subsequent investments made via Automated Clearing House
(ACH). Guggenheim Investments reserves the right to modify its minimum account balance requirements at any time, with or without prior notice to you.
The Fund redeems its shares continuously and investors may sell their shares back to the Fund on any day that the New York Stock Exchange (the NYSE) is open for business (a
Business Day). You will ordinarily submit your transaction order through your financial intermediary or other securities dealers through which you opened your shareholder account or through Guggenheim Investments if you opened your
account directly with the Fund. The Fund also offers you the option to send redemption orders to Guggenheim Investments by mail, fax or telephone.
TAX INFORMATION
Fund distributions are
generally taxable as ordinary income, qualified dividend income, or capital gains (or a combination), unless your investment is in an IRA or other tax-advantaged retirement account.
PAYMENTS TO BROKER-DEALERS AND OTHER FINANCIAL INTERMEDIARIES
If you purchase the Fund through
a broker-dealer or other financial intermediary (such as a bank), the Fund and its related companies may pay the intermediary for the sale of Fund shares and related services. These payments may create a conflict of interest by influencing the
broker-dealer or other intermediary and your sales person to recommend the Fund over another investment. Ask your sales person or visit your financial intermediarys website for more information.
This page
intentionally left blank.
This page
intentionally left blank.
ASGN (NYSE:ASGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
ASGN (NYSE:ASGN)
Historical Stock Chart
From Oct 2023 to Oct 2024